

- November 2022 update

Soren Mogelsvang  
Mycobiotix, Inc  
[Soren.Mogelsvang@mycobiotix.com](mailto:Soren.Mogelsvang@mycobiotix.com)

# Overview

---


## Corporate

- Startup company based on Scandinavian and US technologies
- Experienced, international management team with track record in pharma startups and value creation
- Strong academic and corporate partners

## Assets

- **MCB-2:** A *Methylococcus Capsulatus* Bath (MCB) product for maintaining steroid-free remission in Ulcerative Colitis
  - Licensed from the University of Oslo and developed in collaboration with the University of Copenhagen (Denmark)
- **VLP-1:** Natural Virus-Like-Particles (VLP) for prevention and treatment of SIBO and IBS
  - Licensed from and developed in collaboration with the Universities Berkeley (US) and New Mexico (US)


# MCB-2: An innovative treatment for Ulcerative Colitis



*Methyllococcus capsulatus Bath*

What is it	MCB-1 Preclinical evidence	MCB-2
A non-pathogenic soil bacterium (MCB) and derivative products with therapeutic application in ulcerative colitis and NAFLD	Preclinical intervention studies with MCB normalizes dysbiosis, and improves experimental colitis and NAFLD	New derivative MCB-2 product, enriched from MCB cell lysate, is in development <b><i>New composition of matter patent coverage expected</i></b>

## Production of protein from natural gas




*Methyllococcus capsulatus*

## IP Position



- US Patent No. 11,331,349 issued May 17, 2022
- US Patent Application No. 17/718,798 filed April 12, 2022
- EPO Application Publication No. EP3661532A
  - National stage of PCT application filed August 2, 2018, claiming priority to UK application No. 1712459.5 filed August 2, 2017

# VLP-1: A novel treatment for SIBO and IBS



Micrograph of tailed phages in fecal VLP fractions

What is it	Origin	Preclinical evidence
<p>A patent pending product to prevent, inhibit and treat dysbiosis and associated disorders using Virus-like Particles (VLPs)</p> <p><b><i>Remodeling the gut microbiome</i></b></p>	<p>VLPs can be harvested from a number of sources including plants, fermented foods and fecal matter, virtually eliminating the risks associated with fecal matter transplantation</p>	<p>Transplantation of fecal derived VLPs reduces SIBO in obese mice</p> <p>Transplantation of sauerkraut derived VLPs reduces SIBO in obese mice</p>



## IP Position

- U.S. Application Publication No. US2021121511A1**
  - Compositions (VLPs) and methods to prevent and treat dysbiosis and associated disorders
  - National stage of PCT/US19/32784 filed May 17, 2019 (Priority date of 29 May 2018)
- U.S. Provisional Application No. 63/255,105**
  - Compositions and use of bacteriophages (VLPs) to prevent and treat dysbiosis
  - Application filed on October 13, 2021

# Development and commercialization strategies


## MCB-2: Pharmaceutical development



### Pharmaceutical development

- Complete IND enabling studies
- Submit IND to the US FDA
- Conduct Phase I and IIa clinical studies
- Seek sale/out-licensing to larger pharma company

## VLP-1: Medical food designation



### Medical food development

- Establish GMP process and manufacturing
- Preclinical characterization to support human use
- Conduct clinical testing / "Phase IIa" in patients
- Seek sale/out-licensing to food company

# Recent progress

---

- ✓ Expanded our team to include Professor Britt Koskella from UC Berkeley
- ✓ Granted first US Patent for the MCB technology
- ✓ Established R&D collaborations with the founding laboratories at the Universities of Berkeley and Copenhagen
- ✓ Pitched at the Medicon Valley Microbiome meeting and engaged with potential industry collaborators
- ✓ Met with prospective partners at BIO Europe

# Next steps

---

## **Continue execution of development plans and commercialization strategies**

- Process development and manufacturing for VLP product
- In vivo testing of MCB-1 therapy
- Development of MCB-2 therapeutic
- Continue meeting with prospective partners and acquirers

## **Raise capital to support development and commercialization strategies**

- Explore raising capital from Pitchbook community of investors
- Explore engagement of investment bank to support capital raise
- Submit grant applications for non-dilutive funding
- Build substantial value by 3Q/2023 to initiate engagements with leading VC funds



**Mycobiotix**

For more information

- [Soren.Mogelsvang@mycobiotix.com](mailto:Soren.Mogelsvang@mycobiotix.com)
- [Guy.Yachin@gmail.com](mailto:Guy.Yachin@gmail.com)